The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
Open accessAbstract
BACKGROUNDPyruvate kinase deficiency is caused by mutations in PKLR and leads to congenital hemolytic anemia.Mitapivat is an oral, small-molecule allosteric activator of pyruvate kinase in red cells. METHODSIn this uncontrolled, phase 2 study, we evaluated the safety and efficacy of mitapivat in 52 adults with pyruvate kinase deficiency who were not receiving red-cell transfusions.The patients were randomly assigned to receive either 50 mg or 300 mg of mitapivat twice daily for a 24-week core period; eligible patients could continue treatment in an ongoing extension phase. RESULTSCommon adverse events, including headache and insomnia, occurred at the time of drug initiation and were transient; 92% of the episodes of headache and 47% of the episodes of insomnia resolved within 7 days.The most common serious adverse events, hemolytic anemia and pharyngitis, each occurred in 2 patients (4%).A total of 26 patients (50%) had an increase of more than 1.0 g per deciliter in the hemoglobin level.Among these patients, the mean maximum increase was 3.4 g per deciliter (range, 1.1 to 5.8), and the median time until the first increase of more than 1.0 g per deciliter was 10 days (range, 7 to 187); 20 patients (77%) had an increase of more than 1.0 g per deciliter in the hemoglobin level at more than 50% of visits during the core study period, with improvement in markers of hemolysis.The response was sustained in all 19 patients remaining in the extension phase, with a median follow-up of 29 months (range, 22 to 35).Hemoglobin responses were observed only in patients who had at least one missense PKLR mutation and were associated with the red-cell pyruvate kinase protein level at baseline. CONCLUSIONSThe administration of mitapivat was associated with a rapid increase in the hemoglobin level in 50% of adults with pyruvate kinase deficiency, with a sustained response during a median follow-up of 29 months during the extension phase.Adverse effects were mainly low-grade and transient.(Funded by Agios Pharmaceuticals; ClinicalTrials.govnumber, NCT02476916.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histamine in the regulation of wakefulness
Thakkar, M. M. (2011) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2010.06.004 · Cited by 251
Cited by
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
Metabolomics in cancer research and emerging applications in clinical oncology
Schmidt, D. R., Patel, R., Kirsch, D. G., Lewis, C. A., Vander Heiden, M. G., & Locasale, J. W. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21670 · Cited by 648
Metadata
- Authors
- Grace, R. F., Rose, C., Layton, D. M., Galactéros, F., Barcellini, W., Morton, D. H., van Beers, E. J., Yaish, H., Ravindranath, Y., Kuo, K. H. M., Sheth, S., Kwiatkowski, J. L., Barbier, A. J., Bodie, S., Silver, B., Hua, L., Kung, C., Hawkins, P., Jouvin, M.-H., Bowden, C., & Glader, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-09-05
- Volume
- 381
- Issue
- 10
- Pages
- 933-944
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2971686951
- Cited by
- 164
- References
- 1
- FWCI
- 9.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency. https://app.cochat.ai/papers/10.1056/nejmoa1902678
- The paper
- Grace, R. F., Rose, C., Layton, D. M., Galactéros, F., Barcellini, W., Morton, D. H., van Beers, E. J., Yaish, H., Ravindranath, Y., Kuo, K. H. M., Sheth, S., Kwiatkowski, J. L., Barbier, A. J., Bodie, S., Silver, B., Hua, L., Kung, C., Hawkins, P., Jouvin, M.-H., . . . Glader, B. (2019). Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1902678
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.